IL6 and rheumatoid arthritis: Additionally, an alternative therapeutic application is to utilize CBCRs to target cytokines such as tumor necrosis factor-alpha (TNF-a) or IL-6, which are over-expressed in chronic inflammatory diseases (e.g., rheumatoid arthritis).